AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17303627
Drug: Best antiarrhythmic
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best antiarrhythmic drug therapy
Trial: 4039870
Drug: Acellular preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular preparation
Trial: 29454724
Drug: Normal glucose
RxNorm normalized name: Normal Glucose Control Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal glucose metabolism
Trial: 29454724
Drug: Normal glucose
RxNorm normalized name: Normal Glucose Control Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal glucose metabolism (glycosylated hemoglobin and fasting plasma glucose)
Trial: 29454724
Drug: Abnormal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abnormal glucose metabolism (both diagnostic approaches)
Trial: 26926775
Drug: Rifaximin alone
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin alone (550 mg twice daily for 3 months)
Trial: 26926775
Drug: Rifaximin in
RxNorm normalized name: Product containing rifaximin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin in combination with lactulose (30-60 ml daily for 3 months)
Trial: 21887685
Drug: Bortezomib 1
RxNorm normalized name: bortezomib 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1 mg/m2 × 3 doses (Group 2)
Trial: 21887685
Drug: Bortezomib 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.5 mg/m2 × 3 doses (Group 3)
Trial: 19091394
Drug: Endocrine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine treatment alone (3 months of total androgen blockade followed by continuous endocrine treatment using flutamide)
Trial: 19286422
Drug: Endocrine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine treatment plus radiotherapy
Trial: 19286422
Drug: Endocrine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine treatment alone
Trial: 8917264
Drug: 17‐beta‐estradiol patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17‐beta‐estradiol patches (100 micrograms/24 h)
Trial: 3885664
Drug: Single-dose (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose (1 g) intravenous metronidazole prophylaxis
Trial: 3885664
Drug: No prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylaxis and doxycycline therapy in case of perforation
Trial: 26816605
Drug: Subject-driven titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject-driven titration of BIAsp 30 BID
Trial: 26816605
Drug: Investigator-driven titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator-driven titration of BIAsp 30 BID
Trial: 25337749
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (2 months of ethambutol, isoniazid, rifampicin, and pyrazinamide followed by 4 months of daily isoniazid and rifampicin)
Trial: 25337749
Drug: 6-month regimen
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month regimen (daily moxifloxacin for 2 months followed by weekly moxifloxacin and 1200 mg rifapentine for 4 months)
Trial: 25337749
Drug: 4-month regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-month regimen (daily moxifloxacin for 2 months followed by moxifloxacin and 900 mg rifapentine twice weekly for 2 months)
Trial: 17426742
Drug: Muesli with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muesli with 4 g beta-glucans
Trial: 17426742
Drug: Muesli with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muesli with 3 g beta-glucans
Trial: 14607575
Drug: Oral sibutramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sibutramine (10 mg/day)
Trial: 14607575
Drug: Oral EE‐CPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral EE‐CPA (35 microg‐2 mg/day)
Trial: 14607575
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EE‐CPA plus sibutramine
Trial: 1633069
Drug: Solid micellar
RxNorm normalized name: Douxo Micellar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid micellar solution
Trial: 1633069
Drug: Faster releasing
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faster releasing microemulsion formulation
Trial: 1633069
Drug: Standard soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard soft gelatine preparation
Trial: 27185903
Drug: Active nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active nicotine pressurized metered dose inhaler (pMDI) plus active nicotine patch
Trial: 27185903
Drug: Placebo pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pMDI plus active nicotine patch
Trial: 22919348
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) with conventional medical treatment, 10 sessions within 3-5 days after stroke onset.
Trial: 22919348
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical treatment without HBOT.
Trial: 9464714
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg daily and conjugated equine estrogens 0.625 mg daily (Group C)
Trial: 9464714
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg daily and conjugated equine estrogens 1.25 mg daily (Group D)
Trial: 9464714
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot 3.75 mg every 4 weeks + placebos for progestin and estrogen (Group A)
Trial: 9464714
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg daily and placebo for estrogen (Group B)
Trial: 9464714
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg and conjugated equine estrogens 0.625 mg daily (Group C)
Trial: 9464714
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg and conjugated equine estrogens 1.25 mg daily (Group D)
Trial: 2773686
Drug: Intrathecal baclofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal baclofen administered continuously via programmable pump (90 to 150 micrograms per day)
Trial: 2773686
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine single injection
Trial: 2773686
Drug: Baclofen bolus
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclofen bolus injection (30 to 60 micrograms)
Trial: 26735264
Drug: Oral α-lipoic
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral α-lipoic acid (ALA), betamethasone injection, and NB-UVB
Trial: 26735264
Drug: Placebo, betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, betamethasone injection, and NB-UVB
Trial: 25046949
Drug: Yiqi Huaju
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Huaju Recipe (YHR) combined with routine therapy
Trial: 25046949
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy + placebo (Control)
Trial: 23520670
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol 20 mg
Trial: 23520670
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol 40 mg
Trial: 11413842
Drug: Lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicylate (LAS) 1 g twice daily on Day 1 and 1 g three times daily on Day 2
Trial: 11413842
Drug: Paracetamol (PAR)
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (PAR) 1 g twice daily on Day 1 and 1 g three times daily on Day 2
Trial: 7946588
Drug: Low-dose gamma-interferon
RxNorm normalized name: gamma-interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose gamma-interferon (gamma IFN) at doses of 100, 200, or 400 micrograms, administered daily or weekly for a minimum of 3 months after a 2-week cycle.
Trial: 7946588
Drug: Comparison to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison to other low-dose gamma IFN trials.
Trial: 3680556
Drug: Nimesulide 100
RxNorm normalized name: nimesulide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 100 mg oral doses
Trial: 3680556
Drug: Nimesulide 200
RxNorm normalized name: nimesulide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 200 mg/d PO
Trial: 20961633
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment Arm (STA)
Trial: 20565333
Drug: Memantine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine at 20 mg/day
Trial: 17689932
Drug: Adalimumab (TNFalpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (TNFalpha inhibitor)
Trial: 8848890
Drug: Edrophonium 1
RxNorm normalized name: edrophonium 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 1 mg kg‐1 with atropine 10 micrograms kg‐1
Trial: 1982774
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg propiomazine
Trial: 19049993
Drug: Immediate administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate administration of misoprostol after mifepristone (600 microg vaginally)
Trial: 19049993
Drug: 36-38 h
RxNorm normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 36-38 h administration of misoprostol after mifepristone (600 microg vaginally)
Trial: 19049993
Drug: 36-38 h
RxNorm normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 36-38 h administration of misoprostol
Trial: 19049993
Drug: Immediate administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate administration of misoprostol
Trial: 11231032
Drug: L-threonine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-threonine with pyridoxal 5-phosphate
Trial: 7727908
Drug: Opiate sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opiate sedation plus low dose midazolam (1 mg/hour)
Trial: 30985449
Drug: Restrictive IV
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive IV fluid resuscitation strategy (≤ 60 mL/kg of IV fluid)
Trial: 28453978
Drug: Intra-nasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-nasal administration of Oxytocin
Trial: 25761587
Drug: gonadotrophin‐releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gonadotrophin‐releasing hormone analogue (GnRH‐a) monthly for 6 months
Trial: 25761587
Drug: gonadotrophin‐releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gonadotrophin‐releasing hormone analogue (GnRH‐a)
Trial: 8044013
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine group (CMG) treated with Tongjingbao and Angelicae Complex Injection
Trial: 8044013
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group (WMG) treated with Gentamycin, Dexamethasone, Chymotrypsin
Trial: 3255916
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A of tripotassium dicitrato bismuthate (TDB)
Trial: 3255916
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B of tripotassium dicitrato bismuthate (TDB)
Trial: 28633477
Drug: Loop diuretics
RxNorm normalized name: LOOP DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretics (high doses)
Trial: 28633477
Drug: Diuretics withdrawal
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics withdrawal
Trial: 28633477
Drug: Diuretics (general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (general use)
Trial: 28633477
Drug: Diuretics decrease
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics decrease (from a small randomized study)
Trial: 21401865
Drug: rPSGL-Ig (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rPSGL-Ig (1 mg/kg systemic dose with pretransplant allograft ex vivo treatment)
Trial: 12948258
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ACTH (1 microg) test
Trial: 12948258
Drug: Both low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both low dose and standard dose ACTH tests
Trial: 10890484
Drug: Histamine2-receptor antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Histamine2-receptor antagonists or antacids
Trial: 10170453
Drug: SSRIs (fluoxetine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (fluoxetine, fluvoxamine, sertraline, paroxetine)
Trial: 2947462
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide metered-dose inhaler (40 micrograms four times a day)
Trial: 2947462
Drug: Metaproterenol metered-dose
RxNorm normalized name: metaproterenol sulfate Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol metered-dose inhaler (1,500 micrograms four times a day)
Trial: 30462260
Drug: Rifamycin SV‐MMX®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifamycin SV‐MMX® 400 mg twice daily
Trial: 21094019
Drug: Integrated interpersonal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated interpersonal cognitive‐behavioral group treatment (ICBT)
Trial: 16645969
Drug: Prednisolone 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 7.5 mg/day
Trial: 12553635
Drug: Pure lanolin
RxNorm normalized name: CVS Pure Lanolin 100% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure lanolin cream used twice daily for 4 weeks
Trial: 12553635
Drug: Ammonium lactate
RxNorm normalized name: Ammonium Lactate
DrugBank: Ammonium lactate (DB06768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ammonium lactate 12% cream used twice daily for 4 weeks
Trial: 8840633
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS) 240 mg twice daily (Group 1)
Trial: 8840633
Drug: Sucralfate 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 2.0 g twice daily (Group 3)
Trial: 1458144
Drug: Nifedipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (60 mg/day); 14% required additional diuretics.
Trial: 1458144
Drug: Enalapril (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (40 mg/day); 76% required diuretics.
Trial: 29982727
Drug: GEN-003 30
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN-003 30 µg antigen/25 µg adjuvant
Trial: 29982727
Drug: GEN-003 30
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN-003 30 µg antigen/50 µg adjuvant
Trial: 29982727
Drug: GEN-003 30
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN-003 30 µg antigen/75 µg adjuvant
Trial: 29982727
Drug: GEN-003 60
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN-003 60 µg antigen/25 µg adjuvant
Trial: 29982727
Drug: GEN-003 60
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN-003 60 µg antigen/50 µg adjuvant
Trial: 29982727
Drug: GEN-003 60
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN-003 60 µg antigen/75 µg adjuvant
Trial: 29982727
Drug: GEN-003 60
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN-003 60 µg antigen plus 50 or 75 µg adjuvant
Trial: 26803595
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (1000 mg DHA; 200 mg EPA)
Trial: 26803595
Drug: EPA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA supplementation (1000 mg EPA; 200 mg DHA)
Trial: 25276669
Drug: Chart presenting
RxNorm normalized name: Stachybotrys chartarum
DrugBank: Stachybotrys chartarum (DB10847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chart presenting pregnancy risk with combined pills
Trial: 16258100
Drug: Functional Assessment
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Assessment of Cancer Treatment-Fatigue scores
Trial: 16258100
Drug: Functional Assessment
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Assessment of Cancer Treatment-Endocrine Symptoms scores
Trial: 12114419
Drug: ISIS 3521
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 3521 (2 mg/kg/day as continuous i.v. infusion for 21 of 28 days)
Trial: 12114419
Drug: ISIS 5132
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 5132 (2 mg/kg/day as continuous i.v. infusion for 21 of 28 days)
Trial: 8673001
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (30 mg/day) for up to 2 years
Trial: 2181856
Drug: Glucose polymer
RxNorm normalized name: glucose polymers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose polymer Polycose (100 or 150 g daily for 6 months)
Trial: 7194063
Drug: etofylline clofibrate
RxNorm normalized name: etofylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etofylline clofibrate (Duolip) treatment
Trial: 30241990
Drug: Omega-3 (EPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 (EPA 740 mg and DHA 400 mg daily)
Trial: 26886460
Drug: Brace treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace treatment (thoracolumbosacral orthosis, at least 18 h/d)
Trial: 19526752
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (Xinyue Capsule and compound Tanshinon Tablet)
Trial: 19526752
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional Western medicine alone)
Trial: 18190583
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry capsules (108 mg)
Trial: 18190583
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry capsules (36 mg)
Trial: 18190583
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry capsules (not specified dosage)
Trial: 15668544
Drug: efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: efavirenz (EFV) 600 mg once daily
Trial: 15668544
Drug: nevirapine (NVP)
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nevirapine (NVP) 200 mg twice daily
Trial: 15668544
Drug: nevirapine (NVP)
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nevirapine (NVP) 400 mg once daily
Trial: 15668544
Drug: nevirapine (NVP)
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nevirapine (NVP) 400 mg once daily + efavirenz (EFV) 800 mg once daily